Research & Development

Clinical Trials Overview

Changing the course of human health through bold pursuits in science

As the needs of patients worldwide evolve, Celgene remains dedicated to meeting those needs. Our mission is to use our research to reach those around the globe who experience serious and life-threatening diseases. Clinical trials are a critical part of our R&D pipeline, ensuring that the treatments that reach patients are rigorously tested and effective. Our R&D team works in collaboration with our patient safety team to ensure that patients who participate are involved in well-planned studies.
 
Celgene-sponsored clinical trials

Celgene Corporation and its employees are working relentlessly to provide solutions for unmet medical needs in cancer and debilitating inflammatory diseases.

There are numerous ongoing clinical trials underway at major medical centres worldwide using innovative compounds from Celgene. These investigational compounds are being actively studied in clinical trials for patients with incurable haematological and solid tumour cancers, including:

  • acute myeloid leukaemia
  • chronic lymphocytic leukaemia
  • glioblastoma
  • multiple myeloma
  • myelodysplastic syndromes
  • non-Hodgkin’s lymphoma
  • ovarian cancer
  • pancreatic cancer
  • prostate cancer
  • small cell lung cancer

For information on Celgene-sponsored trials please visit ClinicalTrials.gov. On this website, you will find additional information about the study such as a study description, entry criteria, contact information and facility names where the study is being conducted.

Investigator-initiated Clinical Trials

In addition, we support numerous investigator-initiated trials that use approved therapies or investigational compounds from Celgene.
 
Celgene’s commitment to clinical trials transparency

Celgene is a strong advocate for transparency in clinical trial information. Like other pharmaceutical companies, we are obliged to publish all clinical trial results within one year of marketing authorisation and publically register new clinical trials within 21 days of the first patient being enrolled. This is in line with the International Federation of Pharmaceutical Manufacturers and Associations Code of Practice. Celgene has been, and continues to be, committed to full transparency in relation to all clinical research that it conducts.


UK-CELG150025h
Date of preparation: Feb 2017